Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.

Pfizer's fourth quarter beat expectations on strong sales of its Covid vaccine and pill, bolstering its sales as it seeks to ...

The results cap off a critical year for Pfizer, which has been slashing costs as it recovers from the rapid decline of its ...

CEO Albert Bourla says Pfizer has met the strategic goals it had set for itself in 2024, and that it was ‘executing ...

Activist investor Starboard Value has launched a broadside against Pfizer's leadership under chief executive Albert Bourla, claiming at least $20 billion in value – and possibly as much as $60 ...

Activist investor Starboard Value has taken a stake in Becton Dickinson and is pushing the $72bn medical technology company to sell its life sciences division, according to people familiar with the ...

Two former Pfizer executives drawn into a campaign by activist investor Starboard Value to shake up the company have withdrawn their support for the plan. Pfizer's ex-chair and chief executive Ian ...

FREE TO READ] Critics say fragmented ownership, weak culture and a fixation on financial results have harmed innovation ...

Health-care companies rose after strong earnings from one major drug maker. Novo Nordisk shares rose sharply after the Danish obesity-drug maker posted fourth-quarter Ozempic sales of $4.71 billion, ...

Key highlights: <li /> FGS tops the global M&A rankings, while Prosek surges into second place in deal count; <li /> In Europe, Italy ...

Pfizer Inc. (PFE) exceeded Wall Street expectations in its fourth-quarter and full-year 2024 earnings report, bolstered by ...